In the second step, a library of eleven inhibitors representing multiple leukemia targets, including CDKs, were tested in combination with the resulting Hsp90 inhibitor, for the possible maximization of its anti-leukemic activity. The gene discussed is HSP90AA1; the disease is leukemia.